Whittier Trust Co. Sells 358 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Whittier Trust Co. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,421 shares of the medical research company’s stock after selling 358 shares during the quarter. Thermo Fisher Scientific accounts for approximately 0.7% of Whittier Trust Co.’s holdings, making the stock its 28th biggest holding. Whittier Trust Co.’s holdings in Thermo Fisher Scientific were worth $54,075,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its position in Thermo Fisher Scientific by 3.3% during the 1st quarter. International Assets Investment Management LLC now owns 1,964 shares of the medical research company’s stock valued at $1,134,000 after acquiring an additional 62 shares in the last quarter. Northwest Investment Counselors LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $138,000. Strategic Planning Group LLC boosted its holdings in Thermo Fisher Scientific by 15.1% during the first quarter. Strategic Planning Group LLC now owns 4,707 shares of the medical research company’s stock worth $2,736,000 after buying an additional 617 shares in the last quarter. Austin Private Wealth LLC increased its holdings in Thermo Fisher Scientific by 8.9% in the first quarter. Austin Private Wealth LLC now owns 712 shares of the medical research company’s stock valued at $410,000 after buying an additional 58 shares in the last quarter. Finally, Salvus Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 65.2% during the 1st quarter. Salvus Wealth Management LLC now owns 1,006 shares of the medical research company’s stock valued at $585,000 after acquiring an additional 397 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $7.76 during trading hours on Monday, reaching $593.95. 466,565 shares of the company’s stock were exchanged, compared to its average volume of 1,461,975. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The company’s 50 day moving average is $607.99 and its two-hundred day moving average is $584.23. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $627.88. The company has a market cap of $226.89 billion, a P/E ratio of 37.33, a price-to-earnings-growth ratio of 3.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same period in the previous year, the company posted $5.15 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% on a year-over-year basis. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on TMO. Bank of America raised their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Stifel Nicolaus upped their price objective on shares of Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Wells Fargo & Company began coverage on Thermo Fisher Scientific in a research report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price target for the company. Finally, Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $656.16.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at $1,108,408.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,084 shares of company stock worth $14,094,292 over the last 90 days. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.